LongBio Pharma says FDA clears LP-003 peanut allergy clinical trial application
XLV•FDA clears LP-003 clinical trial application
- LongBio Pharma (Suzhou) won US FDA clearance for its clinical trial application for LP-003 in peanut allergy.
- LP-003 is an anti-IgE antibody candidate designed to block free IgE, aiming to prevent IgE-driven allergic reactions.
